All In Biotech

Drug Trial Radar · NCT00852423

Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria

Last checked: Nov 20, 2026Latest source record: Mar 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,428 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,428

Actual

Start

Jun 2010

Primary completion

Oct 2013

Study completion Apr 2015

Sponsor

Lead sponsor
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute for Medical Research, Tanzania; Kwame Nkrumah University of Science and Technology; Centre Muraz; Kamuzu University of Health Sciences; Tropical Diseases Research Centre, Zambia; Institute of Tropical Medicine(KIT), Amsterdam; Liverpool School of Tropical Medicine
First posted
Feb 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Malaria is the most important human parasitic disease and is responsible of high morbidity and mortality in resource-poor countries. Pregnant women, who are a high-risk group, are almost always excluded from clinical trials; thus, the investigators lack sufficient information on the safety and efficacy of most antimalarials in pregnancy. The recommendation of the World Health Organization to use artemisinin combination therapy (ACT) in the 2nd and 3rd trimester is already implemented in several African countries, however documentation of their efficacy and safety in pregnancy is still limited. Thus, the investigators propose to evaluate the efficacy and safety of 4 ACT(artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine), when used to treat pregnant women with P. falciparum malaria; the results will help to recommend the optimal therapy for this high-risk group in Africa.

Conditions

  • Malaria in Pregnancy

Interventions

  • Dihydroartemisinin-piperaquineDrug

    DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.

  • Artesunate-mefloquineDrug

    MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used

  • Artesunate-amodiaquineDrug

    AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.

  • Artemether-lumefantrineDrug

    AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Failure (PCR adjusted)Time frame: Day 63
  2. Safety profiles including significant changes in relevant laboratory valuesTime frame: Until delivery

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • ISSR/Centre Muraz

    Nanoro, Burkina Faso

  • ISSR/Centre Muraz

    Nazoanga, Burkina Faso

  • Effiduase Government Hospital

    Effiduase, Ghana

  • Kwame Nkrumah University of Science & Technology, Kumasi

    Ejisu Sekyere East, Ashanti Region, Ghana

  • Kwame Nrumah University of Science and Technology, Kumasi

    Juaben Government Hospital, Ashanti Region, Ghana

  • College of Medicine, University of Malawi

    Chikwawa District Hospital, Blantyre, Malawi

  • St Paul Hospital

    Nchelenge, Nchelenge District, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.